Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluticasone
Drug ID BADD_D00945
Description Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965].
Indications and Usage Fluticasone's 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxis[FDA Label][F4364]as well as inflammatory and pruritic dermatoses[F4355]. A [DB00588] nasal spray is indicated for managing nonallergic rhinitis[F4358] while the [DB08906] nasal spray is indicated for treating season and perennial allergic rhinitis[F4361,A177130].
Marketing Status approved; experimental
ATC Code D07AC17; R01AD08; R03BA05
DrugBank ID DB13867
KEGG ID D07981
MeSH ID D000068298
PubChem ID 5311101
TTD Drug ID D0LC6K
NDC Product Code 61919-004; 61919-620; 61919-611
UNII CUT2W21N7U
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C22H27F3O4S
CAS Registry Number 90566-53-3
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytopenia01.08.01.002--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth discolouration07.09.02.001--
Toothache07.09.06.001--
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis10.02.02.006; 24.12.04.027--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.013--Not Available
Intervertebral disc protrusion15.10.01.004--Not Available
Oropharyngeal candidiasis22.07.03.003; 11.03.03.006; 07.05.07.003--Not Available
Contusion12.01.06.001; 15.03.05.007; 24.07.06.001; 23.03.11.002--
Rhinalgia22.12.03.020--Not Available
Viral diarrhoea11.05.04.012; 07.19.02.008--Not Available
Wound23.03.11.043; 12.01.08.009--Not Available
Nasal discomfort22.12.03.012--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Dental discomfort07.09.06.002--Not Available
Haemorrhage24.07.01.002--Not Available
Bacterial infection11.02.01.005--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages